Disperazol Pharma ApS: Financial statements 2024
CVR: 44265761
Source: annual report 2024, Danish Business Authority
01/09/2023 – 08/08/2024
Disperazol Pharma ApS (CVR 44265761) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 40,498 and a net result of DKK 31,622. Equity in the 2024 report amounted to DKK 71,622. The solvency ratio was 88.9%.
- Gross Profit
- DKK 40,498
- Profit/Loss
- DKK 31,622
- Equity
- DKK 71,622
- Total Assets
- DKK 80,554
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Disperazol Pharma ApS
Disperazol Pharma ApS is a Danish company of the type Anpartsselskab based in Humlebæk, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Carl Jörg Michael Graz. In 2025, the company reported a gross profit of DKK -49,965 and a net result of DKK -41,573 compared with DKK 31,622 the year before. Equity in the 2025 report amounted to DKK 30,050.